Can RMSF Present as Atypical HUS?
Yes, Rocky Mountain spotted fever can mimic atypical hemolytic uremic syndrome, presenting with thrombocytopenia, renal failure, and neurologic manifestations that may be confused with TTP or aHUS, but this represents a diagnostic pitfall rather than true aHUS. 1
The Clinical Overlap
RMSF can present with a constellation of findings that closely resemble atypical HUS:
- Thrombocytopenia (common in RMSF) 1
- Acute renal failure (occurs in 19% of hospitalized RMSF patients) 2
- Neurologic manifestations (meningoencephalitis, focal deficits) 1
- Microangiopathic features from rickettsial vasculitis
The CDC guidelines explicitly warn that "RMSF-associated neurologic manifestations, renal failure, and thrombocytopenia have led to confusion with the diagnosis of thrombotic thrombocytopenic purpura (TTP)" 1. This same confusion extends to atypical HUS, as both TTP and aHUS fall under the thrombotic microangiopathy spectrum.
Critical Pathophysiologic Distinction
The mechanism is fundamentally different:
- RMSF: Direct rickettsial infection of vascular endothelial cells causing vasculitis and endothelial injury 1
- Atypical HUS: Dysregulation of the complement alternative pathway (genetic mutations or autoantibodies) 3, 4
While RMSF causes endothelial damage that can trigger hemostatic changes including platelet activation and thrombin generation 5, this is secondary to infection-induced vasculitis, not primary complement-mediated thrombotic microangiopathy.
Diagnostic Approach When Faced with This Dilemma
Look for distinguishing features:
Favoring RMSF:
- Tick exposure history (April-September, wooded/grassy areas) - though 50% don't recall exposure 6
- Characteristic rash (petechial, starting on wrists/ankles, spreading centrally) - but absent in up to 15% 6
- Fever, headache, myalgias as prominent early symptoms 1
- Seasonal/geographic epidemiology 1
- Elevated hepatic transaminases (common in RMSF) 1
Favoring true aHUS:
- No infectious prodrome or tick exposure
- Family history of HUS or complement disorders 4
- Recurrent episodes of thrombotic microangiopathy 4
- Complement testing abnormalities (low C3, genetic mutations, anti-factor H antibodies) 4
Management Implications - Critical for Mortality
This distinction is life-or-death urgent:
- Mortality in untreated RMSF: 25% historically, currently 5-10% overall but 40-50% if treatment delayed to days 8-9 1
- Treatment delay is the single most important mortality risk factor 1
When diagnostic uncertainty exists with features of both:
- Immediately start doxycycline empirically if RMSF is in the differential - do not wait for confirmatory testing 1, 6
- Consider plasma exchange if true TMA features are severe, while awaiting diagnostic clarification
- Send rickettsial serologies (though results won't be available acutely) 7
- Send complement studies (C3, C4, genetic testing, anti-factor H antibodies) 4
Common Pitfall to Avoid
Do not dismiss RMSF because the patient presents with renal failure and thrombocytopenia mimicking aHUS. Case reports document this exact scenario where RMSF was initially misdiagnosed as TTP 7. The patient with severe RMSF may present with:
- Acute renal failure requiring hemodialysis 2, 8
- Thrombocytopenia
- Neurologic involvement
- Multi-organ failure 8
The absence of rash early in illness is particularly dangerous - it delays diagnosis and increases mortality 1. Rash may appear late or be atypical, faint, or difficult to recognize in darker-skinned patients 1.
Bottom Line for Clinical Practice
RMSF does not cause true atypical HUS (complement-mediated TMA), but it can present with an overlapping clinical picture that mimics it. When evaluating any patient with thrombocytopenia, renal failure, and hemolysis during tick season or with potential tick exposure, empirically treat for RMSF with doxycycline immediately while pursuing the full TMA workup. The mortality benefit of early doxycycline in RMSF far outweighs any risk, and treatment delay is lethal 1.